Company Description
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products.
The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure.
Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms.
The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.
| Country | United States |
| IPO Date | Nov 17, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 135 |
| CEO | John H. Tucker |
Contact Details
Address: 2400 District Avenue Burlington, Massachusetts United States | |
| Website | https://www.scpharmaceuticals.com |
Stock Details
| Ticker Symbol | SCPH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001604950 |
| CUSIP Number | 810648105 |
| ISIN Number | US8106481059 |
| Employer ID | 46-5184075 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John H. Tucker | President, Chief Executive Officer, Principal Executive Officer & Director |
| Rachael Nokes | Chief Financial Officer |
| Dr. John Mohr Pharm.D. | Senior Vice President of Clinical Development & Medical Affairs |
| Katherine Taudvin | Vice President of Corporate Affairs & Human Resources |
| Michael D. Hassman | Senior Vice President of Technical Operations |
| Steve Parsons | Senior Vice President of Commercial |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 10, 2025 | 8-K | Current Report |
| Jan 07, 2025 | 4 | Filing |
| Jan 07, 2025 | 4 | Filing |
| Dec 31, 2024 | 10-Q/A | [Amend] Quarterly Report |
| Dec 11, 2024 | 8-K | Current Report |
| Nov 15, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | 8-K | Current Report |